Related references
Note: Only part of the references are listed.Myelodysplastic Syndromes
Mario Cazzola
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Sirolimus for the treatment of multi-resistant pure red cell aplasia
Huijuan Jiang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA)
Claudio Cerchione et al.
ANNALS OF HEMATOLOGY (2015)
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Peter L. Greenberg et al.
BLOOD (2009)
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era;: the GFM experience with EPO and thalidomide
C. Kelaidi et al.
LEUKEMIA RESEARCH (2008)
Myelodysplastic syndrome with pure red cell aplasia shows characteristic clinicopathological features and clonal T-cell expansion
Sa A. Wang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Pure red cell aplasia associated with myelodysplastic syndromes
S Park et al.
LEUKEMIA (2000)
Share Paper
